DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Selumetinib
Selumetinib
(AZD6244) in an in Vivo Model of Childhood Astrocytoma
Could Hbx Protein Expression Affect Signal Pathway Inhibition by Gefitinib Or Selumetinib, a MEK Inhibitor, in Hepatocellular Carcinoma Cell Lines?
MET Or NRAS Amplification Is an Acquired Resistance Mechanism to the Third-Generation EGFR Inhibitor Naquotinib
DNA Replication During Acute MEK Inhibition Drives Acquisition of Resistance Through Amplification of the BRAF Oncogene
Lenvatinib in Advanced, Radioactive Iodine– Refractory, Differentiated Thyroid Carcinoma Kay T
MEK1/2 Inhibitor Selumetinib (AZD6244) Inhibits Growth of Ovarian Clear Cell Carcinoma in a PEA-15–Dependent Manner in a Mouse Xenograft Model
Combinatorial Efficacy of Entospletinib and Chemotherapy in Patient-Derived Xenograft Models of Infant Acute Lymphoblastic Leukemia
CDER Breakthrough Therapy Designation Approvals Data As of December 31, 2020 Total of 190 Approvals
Trastuzumab Emtansine (T-DM1)
Sorafenib/MEK Inhibitor Combination Inhibits Tumor Growth and the Wnt/Β‑Catenin Pathway in Xenograft Models of Hepatocellular Carcinoma
Effect of Kinase Inhibitors on the Technetium-99M Uptake Into Thyroid Carcinoma Cells in Vitro ANNA ANSCHLAG 1, BRANDON H
A Perspective from Clinical Trials
Phase Ib Results of the Rational Combination Of
TFS-CLI 16696 Targeted Therapies and Biomarkers Infographic
Selumetinib Side Effects in Children Treated for Plexiform Neurofibromas
Selumetinib (Koselugo™) EOCCO POLICY
A Focused Biopharmaceutical Company
A Focused Biopharmaceutical Company
Top View
Kinase Drug Discovery 20 Years After Imatinib: Progress and Future Directions
MEK Inhibitors for the Treatment of Non-Small Cell Lung Cancer
NCCN Guidelines for Central Nervous System Cancers Cancer V.1.2021 – Annual 10/23/2020
Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: a University of Chicago Phase II Consortium Trial
The Development of Targeted New Agents to Improve the Outcome For
Novel Third-Generation EGFR Tyrosine Kinase Inhibitors And
Investigating the Potential Clinical Benefit of Selumetinib in Resensitising Advanced Iodine Refractory Differentiated Thyroid C
Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions
Download a List of Pediatric Oncology and Sickle Cell Studies
Bladder Cancer
Oncology Oral, Other Therapeutic Class Review
SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer
Selumetinib Trial Targeting Cutaneous Neurofibromas: Preliminary Findings and Lessons Learned
MEK Inhibition Increases Lapatinib Sensitivity Via Modulation of FOXM1 Sylvia S
The State-Of-The-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies
Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer
E-Learning New Systemic Treatment Options for Radioiodine-Refractory Differentiated and Medullary Thyroid Cancers
Dual-Specificity Protein Phosphatase DUSP4 Regulates Response to MEK
Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML
The MEK Inhibitors Enhance the Efficacy of Sorafenib Against Hepatocellular Carcinoma Cells Through Reducing P-ERK Rebound
New Developments in Targeted Treatments
A Combination of Tyrosine Kinase Inhibitors, Crizotinib and Dasatinib for the Treatment of Glioblastoma Multiforme
Distinct Signaling Events Promote Resistance to Mitoxantrone and Etoposide in Pediatric AML: a Children’S Oncology Group Report
Selumetinib with Radioactive Iodine Therapy for Differentiated Thyroid Cancer – First Line
Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use Between 2013 and 2017
Combining Targeted Therapeutics in the Era of Precision Medicine
Drug Information Center Highlights of FDA Activities – 4/1/2020
Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models Catherine A
Specialty Pipeline MONTHLY UPDATE
Synergistic Effects of Lenvatinib (E7080) and MEK Inhibitors Against Anaplastic Thyroid Cancer in Preclinical Models
Phase Ib Results of the Rational Combination Of
MEK Inhibitor Selumetinib (AZD6244; ARRY-142886)
Phospho-ERK Is a Response Biomarker to a Combination of Sorafenib and MEK
Oncology Agents Policy #: Rx.01.67
Oncofocus Patient Test Report
Biphasic Mathematical Model of Cell–Drug Interaction That Separates
Foundationone Cdx Sample Report
NCI Formulary & NCI-MATCH Trial
Allosteric and ATP-Competitive MEK-Inhibition in a Novel Spitzoid Melanoma Model with a RAF- and Phosphorylation-Independent Mutation
List Item Applications for New Human
Game Changers in Pediatric Cancer Jane De Lartigue, Phd
The MEK Inhibitor Selumetinib Complements CTLA-4 Blockade By
Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020
Response and Toxicity of Small-Molecule Tyrosine Kinase Inhibitors in Patients with Thyroid Carcinoma: a Systematic Review and Meta-Analysis
Selumetinib) Capsules, for Oral Use Increased Creatinine Phosphokinase (CPK): Increased CPK and Initial U.S
Novel ATP-Competitive MEK Inhibitor E6201 Is Effective Against Vemurafenib-Resistant Melanoma Harboring the MEK1-C121S Mutation in a Preclinical Model
Phase Ii Study of the Oral Mek Inhibitor Selumetinib in Advanced Acute
Clinical Trials Appendix Q1 2019 Results Update
Identification of Low-Dose Multidrug Combinations for Sunitinib-Naive and Pre-Treated Renal Cell Carcinoma
Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: a University of Chicago Phase II Consortium Trial
Pharmacological Approaches in Neurofibromatosis Type 1
Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature
Design and Implementation of an Intelligent Framework for Supporting Evidence-Based Treatment Recommendations in Precision Oncology
Bayesian Multi-Source Regression and Monocyte-Associated Gene Expression Predict BCL-2 Inhibitor Resistance in Acute Myeloid Leukemia ✉ Brian S
Current Development Status of MEK Inhibitors
Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2
Lapatinib Resistance in Breast Cancer Cells Is Accompanied by Phosphorylation-Mediated Reprogramming of Glycolysis
The Rocky Road to Personalized Medicine in Acute Myeloid Leukaemia
Pan-RAF and MEK Vertical Inhibition Enhances Therapeutic Response In
NF1 Clinical Pipeline: Active Interventional Drug Therapies
Hazardous Medication Precautions: Personal Protective Equipment (Ppe)
Integrative Analysis of Multi-Platform Reverse-Phase Protein Array Data For
Therapeutic Strategies Targeting Hepatocellular Carcinoma
Selumetinib Inhibits Melanoma Metastasis to Mouse Liver Via
Tyrosine Kinase Receptors in Oncology
Effect of Selumetinib and MK-2206 Vs Oxaliplatin and Fluorouracil In